Nevertheless, the mechanism through which PTEN has been lost and off-target effects remain two important considerations for future clinical trials investigating the targeting of oncomiRs to treat PTEN-deficient prostate cancers [128]. The gene discussed is PTEN; the disease is Familial prostate cancer.